APP and neuroblastoma: Finally, a new generation of ribozymes (hepatitis delta virus (HDV)) has been used in neuroblastoma cells to reduce the expression of amyloid precursor protein (APP) by 70% and the total secretion of amyloid-beta peptides by 30%, thus raising the possibility of ribozymes as therapeutics in AD [40].